Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma Abstract #2259

Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.
Aim(s): To analyze treatment outcomes of PNEC patients.
Materials and methods: Retrospective analysis of all patients PNECs including mixed differentiation with adenocarcinoma component at two oncological centers between 12/2000 and 11/2017.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Dr. med. Leonidas Apostolidis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#117 Synchronous appendiceal neuroendocrine carcinoma and mucinous cystadenocarcinoma: a case report
Introduction: Appendiceal tumors with histological features of both carcinoids and adenocarcinomas are very rare. Carcinomas of the appendix are usually mucinous adenocarcinomas with a tendency to produce peritoneal pseudomyxoma and without metastatic spread until late in the disease course. Carcinoid tumors of the appendix are a common incidental finding.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#597 Primary Hepatic Neuroendocrine Carcinomas Treated with a Combination of Cisplatin and Etoposide as First-Line Chemotherapy: Two Case Reports
Introduction: Because primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare, a standard regimen has not yet been established. However, the combination of etoposide and cisplatin (EP) has been widely used to treat PHNEC.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Shoichi Nakazuru
#974 Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma
Introduction: Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Leonidas Apostolidis
#1095 Efficacy of Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma
Introduction: Therapeutic options for metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC) which is often considered to show a biological behavior similar to NEC.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. med. Leonidas Apostolidis
#1168 Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review
Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the stomach is rare. Gastric NEC occasionally has another component, such as adenocarcinoma, in the same tumor. However, the concurrent occurrence of LCNEC and adenocarcinoma at different sites in the stomach is extremely rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru